Inflammatory Bowel Disease

Lia Pierson Bruner; Anna Marie White; Siobhan Proksell

doi:10.1016/j.pop.2023.03.009

Inflammatory Bowel Disease

Prim Care. 2023 Sep;50(3):411-427. doi: 10.1016/j.pop.2023.03.009. Epub 2023 May 10.

Authors

Lia Pierson Bruner¹, Anna Marie White², Siobhan Proksell³

Affiliations

¹ Augusta University/University of Georgia Medical Partnership, UGA Health Sciences Campus, Russell Hall, Room 235K, 1425 Prince Avenue, Athens, GA 30602, USA. Electronic address: lia.bruner@uga.edu.
² University of Pittsburgh School of Medicine, UPMC Shadyside Hospital, North Tower, Room 307, 5230 Centre Avenue, Pittsburgh, PA 15232, USA.
³ Division of Digestive Health and Liver Disease, University of Miami, Miller School of Medicine, 1120 Northwest 14th Street, CRB, Room 1184, Miami, FL 33136, USA.

PMID: 37516511
DOI: 10.1016/j.pop.2023.03.009

Abstract

Crohn disease and ulcerative colitis, the predominant forms of inflammatory bowel disease (IBD), occur in approximately 1% of the population and are typically characterized by chronic diarrhea (with or without bleeding), abdominal pain, and weight loss. The diagnosis is based on history, physical examination, laboratory studies, and endoscopic evaluation. Extraintestinal manifestations may coincide with or precede IBD diagnosis. Treatments have markedly advanced in the past decade, resulting in improved outcomes. IBD, itself, as well as immunosuppressive therapy can increase rates of certain conditions, making collaboration between primary care and gastroenterology imperative for ensuring comprehensive patient care.

Keywords: Chronic diarrhea; Crohn disease; Immunosuppression; Inflammatory bowel disease; Ulcerative colitis.

Publication types

Review

MeSH terms

Colitis, Ulcerative* / diagnosis
Colitis, Ulcerative* / therapy
Crohn Disease* / diagnosis
Crohn Disease* / therapy
Humans
Inflammatory Bowel Diseases* / diagnosis
Inflammatory Bowel Diseases* / epidemiology
Inflammatory Bowel Diseases* / therapy
Physical Examination
Weight Loss